BlackRock’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.1M | Sell |
5,172,063
-396,318
| -7% | -$1.5M | ﹤0.01% | 3328 |
|
|
2026
Q1 | $21.5M | Sell |
5,568,381
-49,984
| -0.9% | -$197K | ﹤0.01% | 3040 |
|
|
2025
Q4 | $22.1M | Buy |
5,618,365
+11,094
| +0.2% | +$49.1K | ﹤0.01% | 3043 |
|
|
2025
Q3 | $26.2M | Sell |
5,607,271
-124,528
| -2% | -$451K | ﹤0.01% | 2919 |
|
|
2025
Q2 | $17.8M | Buy |
5,731,799
+319,509
| +6% | +$1.03M | ﹤0.01% | 3099 |
|
|
2025
Q1 | $18.3M | Buy |
5,412,290
+55,501
| +1% | +$259K | ﹤0.01% | 2994 |
|
|
2024
Q4 | $30.4M | Sell |
5,356,789
-73,641
| -1% | -$475K | ﹤0.01% | 2779 |
|
|
2024
Q3 | $31.8M | Buy |
5,430,430
+117,813
| +2% | +$857K | ﹤0.01% | 2749 |
|
|
2024
Q2 | $42M | Buy |
5,312,617
+915,173
| +21% | +$7.67M | ﹤0.01% | 2523 |
|
|
2024
Q1 | $40.9M | Buy |
4,397,444
+1,764,765
| +67% | +$14.9M | ﹤0.01% | 2561 |
|
|
2023
Q4 | $22.2M | Buy |
2,632,679
+167,291
| +7% | +$1.21M | ﹤0.01% | 2954 |
|
|
2023
Q3 | $19.1M | Sell |
2,465,388
-12,012
| -0.5% | -$110K | ﹤0.01% | 2966 |
|
|
2023
Q2 | $28.4M | Buy |
2,477,400
+1,653,613
| +201% | +$17.1M | ﹤0.01% | 2814 |
|
|
2023
Q1 | $6.35M | Sell |
823,787
-19,137
| -2% | -$152K | ﹤0.01% | 3529 |
|
|
2022
Q4 | $5.14M | Buy |
842,924
+252,420
| +43% | +$1.43M | ﹤0.01% | 3709 |
|
|
2022
Q3 | $3.5M | Buy |
590,504
+26,289
| +5% | +$168K | ﹤0.01% | 3911 |
|
|
2022
Q2 | $3.33M | Buy |
564,215
+50,060
| +10% | +$338K | ﹤0.01% | 3999 |
|
|
2022
Q1 | $3.92M | Buy |
514,155
+49,319
| +11% | +$220K | ﹤0.01% | 4093 |
|
|
2021
Q4 | $1.26M | Sell |
464,836
-465,899
| -50% | -$1.59M | ﹤0.01% | 4589 |
|
|
2021
Q3 | $2.45M | Sell |
930,735
-11,931
| -1% | -$38.8K | ﹤0.01% | 4243 |
|
|
2021
Q2 | $3.89M | Sell |
942,666
-1,579,754
| -63% | -$7.16M | ﹤0.01% | 3984 |
|
|
2021
Q1 | $11.9M | Sell |
2,522,420
-7,311
| -0.3% | -$49.9K | ﹤0.01% | 3470 |
|
|
2020
Q4 | $18.1M | Sell |
2,529,731
-45,372
| -2% | -$436K | ﹤0.01% | 3059 |
|
|
2020
Q3 | $27.5M | Sell |
2,575,103
-53,664
| -2% | -$630K | ﹤0.01% | 2682 |
|
|
2020
Q2 | $33.2M | Buy |
2,628,767
+221,415
| +9% | +$2.58M | ﹤0.01% | 2506 |
|
|
2020
Q1 | $22M | Buy |
2,407,352
+290,158
| +14% | +$3.33M | ﹤0.01% | 2560 |
|
|
2019
Q4 | $29.5M | Sell |
2,117,194
-9,910
| -0.5% | -$144K | ﹤0.01% | 2668 |
|
|
2019
Q3 | $36.6M | Buy |
2,127,104
+47,550
| +2% | +$998K | ﹤0.01% | 2474 |
|
|
2019
Q2 | $56.6M | Buy |
2,079,554
+185,582
| +10% | +$4.25M | ﹤0.01% | 2248 |
|
|
2019
Q1 | $36.3M | Buy |
1,893,972
+34,954
| +2% | +$455K | ﹤0.01% | 2454 |
|
|
2018
Q4 | $17.5M | Sell |
1,859,018
-4,748
| -0.3% | -$60.9K | ﹤0.01% | 2798 |
|
|
2018
Q3 | $35.3M | Buy |
1,863,766
+18,060
| +1% | +$347K | ﹤0.01% | 2569 |
|
|
2018
Q2 | $36.1M | Buy |
1,845,706
+407,677
| +28% | +$8.06M | ﹤0.01% | 2538 |
|
|
2018
Q1 | $27M | Buy |
1,438,029
+227,266
| +19% | +$4.91M | ﹤0.01% | 2602 |
|
|
2017
Q4 | $20.1M | Buy |
1,210,763
+514,345
| +74% | +$8.82M | ﹤0.01% | 2785 |
|
|
2017
Q3 | $14.3M | Buy |
696,418
+27,985
| +4% | +$316K | ﹤0.01% | 2973 |
|
|
2017
Q2 | $5.99M | Buy |
668,433
+132,706
| +25% | +$1.34M | ﹤0.01% | 3418 |
|
|
2017
Q1 | $7.09M | Buy |
535,727
+531,627
| +12,967% | +$6.45M | ﹤0.01% | 3265 |
|
|
2016
Q4 | $52K | Sell |
4,100
-1,827
| -31% | -$23.5K | ﹤0.01% | 2910 |
|
|
2016
Q3 | $71K | Hold |
5,927
| – | – | ﹤0.01% | 2793 |
|
|
2016
Q2 | $65K | Buy |
5,927
+5,839
| +6,635% | +$71.4K | ﹤0.01% | 2803 |
|
|
2016
Q1 | $1K | Buy |
+88
| New | +$998 | ﹤0.01% | 3571 |
|
Other funds holding VYGR
AC
VPC
OM
BlackRock's VYGR Position: Q2 2026 in Review
BlackRock reduced its Voyager Therapeutics (VYGR) stake by 7.1% in Q2 2026, selling an estimated $1.5M and leaving 5,172,063 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3328.
BlackRock first reported a position in VYGR in Q1 2016 and has held it in 42 quarters since. The position peaked at $56.6M in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- BlackRock held 5,172,063 shares of Voyager Therapeutics worth $18.1M as of Q2 2026.
- BlackRock sold 396,318 Voyager Therapeutics shares in Q2 2026, an estimated $1.5M.
- Voyager Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3328 holding.
- BlackRock first reported a position in Voyager Therapeutics in Q1 2016 and has held it in 42 quarters since.
- BlackRock's Voyager Therapeutics position peaked at $56.6M in Q2 2019.
- 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.